[tw0122]

Reverse split in June looks primed for another pump. Buy a few for the quick upcoming pump and dump show

[glenn1919]

SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

[TheFinalCD]

MOON

[Monksdream]

SLRX 10Q due AUGUST 5

[Stockexpertpro]

SLRX 500K Float FDA News Coming Watch for a WINT Type move to the upside trading under cash with FDA News Imment Trading under Cash with over 7$ per share

[glenn1919]

SLRX.......................................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

[TheFinalCD]

https://dilutiontracker.com/app/search/SLRX?a=dbb88c

[trader59]

Brazen manipulation, computer generated wash trading. The O/S has turned over 100X's today. Don't get trapped with grossly overpriced stock.

[Awl416]

Yikes

[glenn1919]

SLRX.........................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

[glenn1919]

SLRX..................................https://stockcharts.com/h-sc/ui?s=SLRX&p=W&b=5&g=0&id=p86431144783

[Monksdream]

SLRX new 52 week low

[PonkenPlonken]

chart looks ready

[tw0122]

3.40s

[Monksdream]

SLRX new 52 week low

[Monksdream]

SLRX 1 for 8 Monday 6/17

[Monksdream]

SLRX new 52 lo

[Monksdream]

SLRX new 52 week low

[Awl416]

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

[81vette]

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders,announced 1/5/23,next greatest cure for cancer is possible>targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled “Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.” The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037.
Targeted protein degradation (TPD) takes advantage of the body’s own degradation system to promote the selective elimination of disease-causing proteins. The newly issued patent is based on the molecular glue eragidomide (CC-90009) that is known to target the degradation of GSPT1, a protein that is highly expressed in numerous cancers, including hematologic and solid tumors.

[81vette]

got the bounce off 200ma @ $3.30 ,float rotated 1x in 1 hr wow!!!

[81vette]

zero borrow,no shares to short,gap filled, summit speaking 26th

[81vette]

2m float,target $70.00,institution 17%,vol 4Xs ave,#1on my scanner,world looking at it now

[81vette]

nasdaq promo out,thinking about buying!!!

[urge2surge]

Top picks here would be $GMER $NILE $SNPX. Best reward to risk plays. Honorable mentions, $NBRI $PGAS $NXGT
I'm done posting on this board. But it's been nice communicating with you. I'm vested in all the above so maybe we'll continue on any of the other boards.
Good luck to you.

[corvatsch]

the return of money in the OTC due to the rise in inflation is interesting.
I am currently exposed on XBIO Xenetic Biosciences at Nasdaq.
I have a small position on a very risky OTC stock.
(SMFX) SAM TRADE. has an ongoing process for an undeclared license in Singapore., but if it resolves to a small fine, it could take off ....

p.s.
I will wait NVDA in the $ 140-150 area before a buy ..

[urge2surge]

They may have started with good intentions but only a very few small bios ever materialize into something of real substance. Most are just ATM plays, banking off of hopeful and or naive investors. Took me a long time to see the forest from the trees. Better late than never. I monitor a lot of stocks and when I see weak bios issuing ATM I make a point to never re enter. A private placement is the best case scenario. They don't deserve my wallet or attentions thereafter. Eventually, with the market showing no signs of reversing for years to come, if at all, most will be delisted or bk. You can only play the investors to a certain point. With investors running for the exits, they'll be soon finding themselves with shut doors, as most won't be able to stay off creditors or debt liabilities. Good.

At this point in the pre hyper inflation recession period, I'm seeing an early return of monies into the OTC sector. Fwiw, here's a decent article on a few reward to risk plays that actually might produce some stellar returns. I know I can use it. Ugh...

https://insiderfinancial.com/4-otc-stocks-to-boost-your-portfolio-cybl-dpls-gmer-lclp/183146/

Glta

[corvatsch]

you are 100% right ....
they are management to be arrested immediately, sucking shareholders' money on the hope of a cure. incompetent and thieves !!!

[urge2surge]

I've monitored this after making some coin a long time ago. Since then, been a dog and rightly so. Seeing a lot of small cap bios that have issued ATM at beaten down low stock prices. Why? Because they inherently have nothing of value to offer except sell shares, get a paycheck, and continue their facade. It's happening on a lot of these plays in this sector sad to say. Most should be delisted and or bought out primarily for the NOLS write offs to big pharma. Most of these dogs will and should fail. Anybody that knows anyone with cancer, knows that very little has changed beyond chemo and radiation. Despite all the monies supposedly spent on advancements, treatments haven't changed. Immunotherapy treatments are starting to gain treatment protocols, and experimental last ditch efforts on stem cells, but the majority is still chemo and radiation.
Anyways, I've sworn off these dead end oncology small bios, as little if any return on investments other than disappointments. I especially write off any that issue ATM at this sub $1 low of years prices. Looking at a reverse split followed by wash rinse and repeats. Corporate should be ashamed of themselves for terrible fiduciary management of shareholders monies. But they don't care. So vote with your wallet and find real companies with product and revenues. Let these dogs die as they should.
Glta

[corvatsch]

as I wrote SLRX is a disaster from all points of view ....
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

https://ih.advfn.com/stock-market/NASDAQ/salarius-pharmaceuticals-SLRX/stock-news/87886271/salarius-pharmaceuticals-inc-announces-2-3-mill

[corvatsch]

I don't like it at all, when they ask for stock reversal splits ...
they are admitting that the stock will not be able to rise above the dollar on its own.
as always after the equity reversal split, the stock will continue to fall further !!!

[DD-214]

SLRX - https://twitter.com/salariuspharma/status/1503767481214717957?s=21

[axelvento]

HI buy insider slrx: $ 0.391 2022-03-09

https://www.secform4.com/filings/1615219/0001615219-22-000019.htm

https://www.secform4.com/filings/1615219/0001615219-22-000018.htm


H.C. Wainwright analyst Michael King reiterated a Buy rating on Salarius Pharmaceuticals (SLRX – Research Report) today and set a price target of $4.00.

[corvatsch]

hello AXEL,
do you think SLRX or STAB is more interesting in the medium-long term (one year)?
THANK YOU.

[axelvento]

news: https://finance.yahoo.com/news/salarius-pharmaceuticals-reports-business-highlights-210500786.html

[corvatsch]

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
February 17 2022 - 02:01PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that David Arthur, CEO of Salarius Pharmaceuticals, will present during the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference on Thursday, February 24, 2022.
During the presentation, Mr. Arthur will highlight Salarius’ business and recent corporate achievements, including the ongoing Phase 1/2 clinical trial of seclidemstat and the company’s recent purchase of a portfolio of targeted protein degradation assets, led by SP-3164.

[corvatsch]

let's hope so....
the current market capitalization is $ 21 million, at $ 5 it would be $ 220 million. it wouldn't even be that high.

[axelvento]

Scroll over to see
https://www.marketbeat.com/stocks/NASDAQ/SLRX/price-target/

[corvatsch]

hi Axel,
do you have the information site of the analyst target?
thank you.

[axelvento]

Seclidemstat has a manageable safety profile with proof-of-concept preliminary activity in heavily pretreated pts with relapsed/refractory ES. These data support the planned Phase 2 expansion of seclidemstat as single agent and in combination with chemotherapy in ES and other sarcomas that share similar translocations. Clinical trial information: NCT03600649'.

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.11514

[axelvento]

Insider buying vs selling: https://www.wallstreetzen.com/stocks/us/nasdaq/slrx/ownership

[axelvento]

VANGUARD GROUP INC 1,585,020 SHARES HELD!


Institutional Ownership 14.84 %


https://www.nasdaq.com/market-activity/stocks/slrx/institutional-holdings

[axelvento]

O/S 45.21M - FLOAT 45M nice structure!

[axelvento]

Target by analysts: $5

[axelvento]

With this acquisition, Salarius has gone from a company with a single clinical-stage investigational drug asset, seclidemstat, to a company with a multi-prong internal pipeline built around two exciting and distinct fields of cancer drug research – protein inhibition and targeted protein degradation.....


Insiders are in possession of 0.40% of company’s total shares while institution are holding 19.26 percent of that, with stock having share float percentage of 19.34%.

next quarterly report between March 16 and March 21 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.


alert: Compliance for the $1.00 bid rule must be regained by 05/16/2022. Not including the possibility of a 180 day extension


we have all the cards in hand!

[corvatsch]

Under the terms of the agreement, DeuteRx will receive from Salarius an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock. Based upon the success of SP-3164, DeuteRx is also entitled to receive up to $53 million in future clinical and regulatory event-driven milestone payments and sales achievement milestone payments of up to $135 million, as well as escalating royalties on net sales. Additionally, DeuteRx is eligible to receive event-driven clinical, regulatory and sales achievement milestone payments of up to $84 million, as well as escalating royalties on net sales, for each of two future products.


hello AXELVENTO,
by this agreement, DeuteRx has a great advantage over SALARIUS. ? how do you see the situation in the medium term?
thank you.

[axelvento]

news out!
http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-expands-oncology-pipeline-through

[corvatsch]

from this news at the end of October, the stock has practically halved $ 0.49 ...
how is it possible ? from these levels it capitalizes 22 MILLION ...
are you still in on this title?
thank you.

[axelvento]

33 million in cash!!

'Seclidemstat also has the potential for treating various other cancer types. For instance, MD Anderson recently announced an investigator initiated trial studying seclidemstat in hematological cancers. In addition, Salarius hopes to study seclidemstat in othe